Xceleron, a provider of bioanalytical AMS services for accelerated early drug development, has formed a partnership with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics. The partnership will offer drug developers simpler and more robust early clinical investigations.
Non-optimized or incomplete pharmacokinetic analyses commonly result in additional expenses and lost time over the course of a development program; such problems frequently become evident during expensive proof-of-concept investigations. Thoroughly understanding the pharmacokinetics of a drug or biologic in clinical phase I studies allows investigators to make decisions earlier. Phase I pharmacokinetic investigations must be properly designed to ensure that their results will translate into proof-of-concept and must be conducted in a cost-effective manner.
The partnership between Xceleron and Kinetigen is ideally suited to provide powerful and cost-effective investigations of phase I drug pharmacokinetics. Kinetigen specializes in complex pharmacokinetic analyses and overall clinical pharmacology strategy. Xceleron uses AMS (Accelerator Mass Spectrometry) to gain analytical insight across a broad range of asset classes and matrix types. Together, Xceleron and Kinetigen leverage a conventional phase I approach to expand the knowledge base and value of intellectual property before the onset of expensive late-phase clinical investigations.
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, CEO of Xceleron.
Dr. Geoffrey Banks, CEO of Kinetigen, added, “Our partnership with Xceleron is very synergistic. Matching Kinetigen’s pharmacokinetic expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of phase I PK data.”
